CategorySymptoms and treatments

ProfK launched ChariotMS last week. Case reports of COVID-cladribine

There has not been as much information about COVID-19 and oral cladribine as has occurred with anti-CD20. In view of the launch of ChariotMS by ProfK. This case report is welcome news in that both people who developed COVID were not hosptialised and recovered. They were relatively young and may be expected to recover but the fact that they had COVID shortly after treatment when the depleting...

High Dose Biotin another one bites the dust in progressive MS

Biotin was a found by a chance occurrence. Biotin is one of those drugs you can get your hands on and you can eat 30 tablets a day to get the high dose in the trials. Some of you will be munching on these. But just as many of you will be ordering lipoic acid based on a drug selection study, there is no replacement for a clinical trial at present. This nutriceutical come pharmaceutical has been...

ChariotMS is on a roll…

I’ve been neglecting my blogging duties, but I have an excuse, which is that I had the team and myself on ‘slogging’ duties to get ChariotMS underway:-) ChariotMS is an ‘investigator-led’ trial, and that really means doing all related jobs yourself, from protocol writing to participant-information & consent sheets, case report forms, database, statistics...

Ibudilast to save nerves maybe

As COIVD-19 vaccines approaches a reality, the anti-VAXers are out, giving us a conspiracy theory. The Government is going to force you to be vaccinated….but lets face it they don’t have enough vaccine to treat everybody…Do you really thing that this force going to happen. Think stop talking SH1. Next up there will be reasons why you shouldn’t vaccinate such as vaccine RNA...

Guest Post:Cell Therapies to Treat Viral Infections

Today we are delighted to have a guest post by Dr Chris Lazarski to talk about their interesting work. Background: Vaccines are a critical tool to protect the majority of people from viral infection.  However, some people require a more involved treatment strategy to treat persistent viral infections.  These people may be immune suppressed because they have received a bone marrow...

AHSCT more effective than alemtuzumab

This says what I think we know, but there is a trial ready to go to put this question to bed. The people taking HSCT were more active thand the alemtuzumab treated group and in terms of relapse there was not alot of difference between the two Zhukovsky C, Sandgren S, Silfverberg T, Einarsdottir S, Tolf A, Landtblom AM, Novakova L, Axelsson M, Malmestrom C, Cherif H, Carlson K, Lycke J, Burman J...

Could the new animal “Cure of the week” be the Cure

You want to hear about studies on cures. As a Jaded old Mouse I have been there before and we get “cure of the week” every week in MouseLand. But nothing translates into human benefit…so far. You asked about this one hitting the news This week we have Casella et al. Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in...

The second wave hits

In the face of a second lock down Europe is waking up to the realization that COVID19 is now here to say. If something is here to say, the chances are that it would become the norm. For most this will mean wearing face masks, limiting social contact and being careful on a day to day based on background population infection rates. For those with MS and others on regular immunosuppressants, things...

Phenytoin in acute optic neuritis

The original phenytoin study, published by the team at University College London, demonstrated that the use of phenytoin (- sodium channel blocker) for three months after the onset of acute optic neuritis was neuroprotective. Slide from Medscape education We have now analysed the blood samples taken for neurofilament analysis and found that neurofilament heavy chain levels (as opposed to light...

T time…Is it time for Otilimab/ mavrilimumab?

Otilimab and mavrilimumab are human antibodies that block Granulocyte-macrophage colony stimulating factor (GM-CSF) of the GM-CSF receptor respectively. The may block macrophage function but could also block a new T cell type implicated in MS, which secretes GM-CSF J. Rasouli et al. A distinct GM-CSF+ T helper cell subset requires T-bet to adopt a TH1 phenotype and promote neuroinflammation...

Translate

Categories

Recent Posts

Recent Comments

Archives